---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014426"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:55:21.101122+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q2 core lung diag revenue $7.3M (+52% YoY); net loss $15.8M; reaffirms 2022 guidance

## Summary
- Core lung diagnostic revenue $7.3M, up 52% YoY; total revenue $11.0M down 8% due to COVID test decline.
- Net loss $15.8M, up 39% driven by loss on extinguishment from Indi contingent consideration restructuring.
- Cash and equivalents $28.7M (incl. $5.1M restricted); raised net $27.3M in debt/equity during Q2.
- Reaffirmed 2022 revenue outlook of $37.5M-$39.5M; Medicare coverage secured for Nodify CDT test.
- Announced strategic pacts with Philips, MSK, and Bio-Rad to co-develop an MRD test for solid tumors.

## SEC filing metadata
- accession: 0000950170-22-014426
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017022014426/0000950170-22-014426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017022014426/bdsx-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014426
- JSON: https://secwatch.observer/filing/0000950170-22-014426.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.